The Center for Assisted Reproduction features INVOcell on KFAA-TV (Dallas) Good Morning Texas
BEDFORD, Texas and MEDFORD, Mass., May 1, 2018 /PRNewswire/ — INVO Bioscience, Inc. (OTC: IVOB), a medical device company granted FDA clearance for the first Intravaginal Culture System, INVOcell™, today announced that Dr. Kevin Doody, MD and Dr. Kathleen Doody, MD, founders of The Center for Assisted Reproduction (Care Fertility), discussed the advantages of their “Effortless IVF” process and the prominent role of INVOcell in the process. They were guests on Good Morning Texas on Dallas’ KFAA-TV last week on Thursday, April 26, 2018 in recognition of National Infertility Awareness Week. Based in Bedford, Texas, The Center for Assisted Reproduction has been a pioneer of assisted reproductive technologies in the north Texas region.
Dr. Kevin Doody, said, “Our Effortless IVF program is different in a number of ways from traditional (“in-vitro fertilization”) IVF programs. It’s more accessible; it’s more affordable; and more natural. Normally with traditional IVF there would be numerous office visits and blood draws leading up to egg retrieval and significantly driving up costs. In our Effortless IVF program, we combine the INVOcell technology with a streamlined monitoring approach which reduces the office visits to a fraction of what they are with traditional IVF; making it easier and more affordable – by about half the cost of conventional IVF. We believe that INVOcell opens the door to a broad new audience of couples looking to start or expand their families.”
INVOcell has the ability to significantly transform the way in which doctors assist infertile patients to become pregnant in a simpler, more natural and cost-effective manner. INVOcell is a patented medical device used in the treatment of infertility that enables egg fertilization and early embryo development to take place in the woman’s body, in vivo. The simplistic INVO can be easily performed in an appropriately trained physician’s office without the need for expensive overhead.
“We have seen many patients who would like to undergo IVF treatment, but the time and financial requirements of the procedure can be prohibitive,” commented Dr. Kathleen Doody. “With the development of the new INVOcell device, we are able to greatly reduce the cost of treatment by virtually eliminating all lab costs. The INVOcell device is a new product that allows the incubation period of IVF treatment to take place inside the prospective mother, rather than in a lab.”
On the best candidates for Effortless IVF, Dr. Kathleen Doody, concluded, “While age is always an independent predictor of success – younger women having the higher pregnancy rates – we’ve had success with women into their 40s with Effortless IVF.”
Care Fertility is conducting a drawing for a complementary Effortless IVF treatment cycle for a qualified couple. It includes the initial evaluation from the Care Fertility staff, the medications used to stimulate the ovaries, and the Effortless IVF cycle itself. Those wishing to enter the drawing can do so at www.effortlessivf.com. The winner will be announced on May 5, 2018.
About The Center for Assisted Reproduction (Care Fertility)
Co-founded in 1989 by Drs. Kevin Doody and Kathleen Doody, The Center for Assisted Reproduction has been a pioneer of assisted reproductive technologies in the north Texas region with several firsts including the first ICSI pregnancies and the first to successfully implement a blastocyst culture system. CARE Fertility also had the first pregnancy in the region with a pregnancy following embryo biopsy and pre-implantation genetic testing for cystic fibrosis. The Center is an independent facility which includes a CLIA certified endocrine / andrology laboratory, a CAP certified embryology (IVF) laboratory and an accredited ambulatory surgical center (ASC). Unlike other clinics, egg retrievals are performed in the safety of an accredited surgical center onsite at CARE. The Center has longstanding relationships and has contracted with virtually all major managed care organizations allowing patients to get referrals with relative ease. For more information, please visit: https://www.embryo.net/.
About INVO Bioscience
We are a medical device company focused on creating simplified, lower cost treatments for patients diagnosed with infertility. Our solution, the INVO Procedure, is a disruptive new technology. The INVO Procedure is a revolutionary in vivomethod of vaginal incubation that offers patients a more natural and intimate experience. Our lead product, the INVOcell, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (“ART”). The INVOcell is the first Intravaginal Culture (“IVC”) system in the world used for the natural in vivoincubation of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization (“IVF”) and Intrauterine Insemination (“IUI”). Our mission is to increase access to care and expand fertility treatment across the globe with a goal to lower the cost of care and increase availability of care. For more information, please visit https://invobioscience.com/.
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
INVO Bioscience, Inc.
Kathleen Karloff, CEO
978-878-9505 ext. 504